These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34692478)

  • 21. The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors.
    Chen L; Zhao R; Sun H; Huang R; Pan H; Zuo Y; Zhang L; Xue Y; Li X; Song H
    Front Pharmacol; 2022; 13():833584. PubMed ID: 35795575
    [No Abstract]   [Full Text] [Related]  

  • 22. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer.
    Zhang T; Xue W; Wang D; Xu K; Wu L; Wu Y; Zhou Z; Chen D; Feng Q; Liang J; Xiao Z; Hui Z; Lv J; Wang X; Deng L; Wang W; Liu W; Wang J; Zhai Y; Wang J; Bi N; Wang L
    Radiother Oncol; 2021 Mar; 156():244-250. PubMed ID: 33418003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy.
    Ali WAS; Hui P; Ma Y; Wu Y; Zhang Y; Chen Y; Hong S; Yang Y; Huang Y; Zhao Y; Fang W; Zhao H; Zhang L
    Ann Transl Med; 2021 Nov; 9(22):1639. PubMed ID: 34988148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade.
    Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Ruggeri EM
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
    Kazandjian D; Gong Y; Keegan P; Pazdur R; Blumenthal GM
    JAMA Oncol; 2019 Oct; 5(10):1481-1485. PubMed ID: 31343662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
    Wang W; Huang Z; Yu Z; Zhuang W; Zheng W; Cai Z; Shi L; Yu X; Lou G; Hong W; Zhang Y; Chen M; Song Z
    Front Oncol; 2020; 10():572853. PubMed ID: 33163403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of dNLR and LIPI scores on the prognosis of elderly patients with non-surgical treatment of non-small cell lung cancer].
    Xie JH; Liu MM; Sun NN; Zhang L; Zhang HZ
    Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):975-980. PubMed ID: 36164700
    [No Abstract]   [Full Text] [Related]  

  • 29. A composite indicator of derived neutrophil-lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors.
    Chen S; Guo S; Gou M; Pan Y; Fan M; Zhang N; Tan Z; Dai G
    Front Oncol; 2022; 12():951985. PubMed ID: 36387152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
    Arıkan R; Alkış H; Işık S; Yaşar A; Çelebi A; Majidova N; Sever N; Adlı M; Demircan NC
    Cureus; 2023 Jun; 15(6):e40548. PubMed ID: 37465788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer.
    Zhai X; Jing X; Li J; Tian Y; Xu S; Wang M; Zhu H
    Front Oncol; 2020; 10():556275. PubMed ID: 33102221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
    Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
    Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
    Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity.
    Moratiel Pellitero A; Zapata Garcia M; Gascon Ruiz M; Arbones-Mainar JM; Lastra Del Prado R; Isla D
    World J Oncol; 2024 Apr; 15(2):223-238. PubMed ID: 38545481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy.
    Araki T; Tateishi K; Komatsu M; Sonehara K; Kanda S; Hanaoka M; Koizumi T
    Thorac Cancer; 2022 Apr; 13(7):1006-1013. PubMed ID: 35156310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
    Hopkins AM; Kichenadasse G; Abuhelwa AY; McKinnon RA; Rowland A; Sorich MJ
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.
    Lu J; Du L; Lei X; Zhang Z
    Cancer Med; 2023 May; 12(10):11334-11343. PubMed ID: 36951584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.
    Tanaka S; Uchino J; Yokoi T; Kijima T; Goto Y; Suga Y; Katayama Y; Nakamura R; Morimoto K; Nakao A; Hibino M; Tani N; Takeda T; Yamaguchi H; Tachibana Y; Takumi C; Hiraoka N; Takeshita M; Onoi K; Chihara Y; Taniguchi R; Yamada T; Matsui Y; Hiranuma O; Morimoto Y; Iwasaku M; Tokuda S; Kaneko Y; Yamada T; Takayama K
    Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score.
    Galvano A; Peri M; Guarini AA; Castiglia M; Grassadonia A; De Tursi M; Irtelli L; Rizzo S; Bertani A; Gristina V; Barraco N; Russo A; Natoli C; Bazan V
    Ther Adv Med Oncol; 2020; 12():1758835920942378. PubMed ID: 32849916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Predictive Value of LIPI and iSEND Immune Scoring System 
in Immunotherapy of Advanced Non-small Cell Lung Cancer].
    Luo Y; Wang X; Wang Y; Zhang G
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):803-810. PubMed ID: 36419394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.